0
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial. (linkinghub.elsevier.com)
Authors:
Puliafito BR
… Maus MV
Journal:
The Lancet
Published:
2026-11-17
DOI:
https://doi.org/10.1016/S0140-6736(26)01806-4
Comments
Login to comment.
No comments yet. Be the first!